The company's stock price more than doubled yesterday to close at 85.50 pence as investors breathed a sigh of relief that the European Medicine's Agency's Committee for Medicinal Products for Human Use has given the thumbs up for Flutiform's (fluticasone and formoterol) approval in the region as a treatment for asthma.
The drug's road to market has been less than smooth; its marketing application was passed to the EMA last year after member states failed to reach a unanimous decision through the decentralised procedure, with one country disagreeing with the positive benefit/risk assessment made by reference state the United Kingdom.
The US Food and Drug Administration also rejected the New Drug Application for Flutiform as a treatment for asthma in January 2010, and a subsequent 74-page complete response letter the following June meant additional clinical work for extra data on dosing, substantially delaying its approval there and costing the firm its marketing agreement with Abbott.
The recommendation by the CHMP means that, if all goes well, Flutiform could be on pharmacy shelves in some countries in Europe in as little as three months depending on individual pricing and reimbursement negotiations, where it will compete for market share with GlaxoSmithKline’s Advair (salmeterol and fluticasone) and AstraZeneca’s Symbicort (budesonide and formoterol).
Skyepharma has long said that the approval and launch of Flutiform in Europe, where it will be marketed by Mundipharma, is pivotal to the value and longer-term cash-generative potential of the group.
According to IMS data, the preventative asthma/COPD European market size in 2010 was around to be £5.5 billion, with a four-year compound annual growth rate of 6.6%. With preventative asthma treatments comprising well over half this market, the potential for Flutiform is certainly substantial.
Exparel launch triggers $10 million
Further bolstering the firm's stock was the news that it has received a £6.2 million milestone payment from Pacira Pharmaceuticals (SkyePharma's former Injectables Business) triggered by the launch of Exparel (bupivacaine liposome injectable suspension) in the US.
The drug combines bupivacaine with DepoFoam, a product delivery technology that delivers medication over a desired timeframe, and has received US approval for administration into the surgical site to analgesia after surgery.
According to SkyePharma, the DepoFoam platform allows a single dose of Exparel to deliver the painkiller bupivacaine over time, providing analgesia with reduced need for opioid drugs for up to 72 hours.
The company could earn "substantial additional milestone payments" on the product and is entitled to 3% of its net sales in the US.The company's stock price more than doubled yesterday to close at 85.50 pence as investors breathed a sigh of relief that the European Medicine's Agency's Committee for Medicinal Products for Human Use has given the thumbs up for Flutiform's (fluticasone and formoterol) approval in the region as a treatment for asthma.
The drug's road to market has been less than smooth; its marketing application was passed to the EMA last year after member states failed to reach a unanimous decision through the decentralised procedure, with one country disagreeing with the positive benefit/risk assessment made by reference state the United Kingdom.
The US Food and Drug Administration also rejected the New Drug Application for Flutiform as a treatment for asthma in January 2010, and a subsequent 74-page complete response letter the following June meant additional clinical work for extra data on dosing, substantially delaying its approval there and costing the firm its marketing agreement with Abbott.
The recommendation by the CHMP means that, if all goes well, Flutiform could be on pharmacy shelves in some countries in Europe in as little as three months depending on individual pricing and reimbursement negotiations, where it will compete for market share with GlaxoSmithKline’s Advair (salmeterol and fluticasone) and AstraZeneca’s Symbicort (budesonide and formoterol).
Skyepharma has long said that the approval and launch of Flutiform in Europe, where it will be marketed by Mundipharma, is pivotal to the value and longer-term cash-generative potential of the group.
According to IMS data, the preventative asthma/COPD European market size in 2010 was around to be £5.5 billion, with a four-year compound annual growth rate of 6.6%. With preventative asthma treatments comprising well over half this market, the potential for Flutiform is certainly substantial.
Exparel launch triggers $10 million
Further bolstering the firm's stock was the news that it has received a £6.2 million milestone payment from Pacira Pharmaceuticals (SkyePharma's former Injectables Business) triggered by the launch of Exparel (bupivacaine liposome injectable suspension) in the US.
The drug combines bupivacaine with DepoFoam, a product delivery technology that delivers medication over a desired timeframe, and has received US approval for administration into the surgical site to analgesia after surgery.
According to SkyePharma, the DepoFoam platform allows a single dose of Exparel to deliver the painkiller bupivacaine over time, providing analgesia with reduced need for opioid drugs for up to 72 hours.
The company could earn "substantial additional milestone payments" on the product and is entitled to 3% of its net sales in the US.
For the latest updates on the stock market, PRESS CTR + D or visit Stock Market Today For the latest updates PRESS CTR + D or visit Stock Market news Today
Related Post:
uk stock market
- How payday loan bullies are stealing your cash
- UK stock to watch Invensys, Taylor Wimpey, Vodafone nov 12 2012
- UK Economic out of the double-dip recession report today oct 25 2012
- UK retail sales report september 26 2012
- average payment to a UK bank 2011
- Royal Bank of Scotland shares prices for 8/31/2012
- Lloyds Banking shares prices for 8/31/2012
- London stocks FTSE outlook 8/31/2012
- official figures US economic growth q2 2012
- London stock market closed 8/27/2012
- ETFs Stocks to watch week 27-31 august 2012
- UK Equity markets market closed july 24, 2012
- UK stock market week july 23-27, 2012
- UK Bank Scandals as profits rise, HSBC, Lloyds Banking Group, Royal Bank of Scotland and Barclay
- UK banks need more capital to withstand an escalation in the eurozone crisis
- FTSE 100 stock outlook june 7 2012
- London stock market FTSE 100 down may 23 2012
- impact of Greek exit from Eurozone on UK Economy
- FTSE 100 outlook open may 14 2012
- FTSE stock closed today april 30 2012
- FTSE 100 Risers, Fallers april 26 2012
- Tesco market shares april 2012
- FTSE100 expected to open lower today april 23 2012
- British stock market focus next week april 23-27 2012
No comments:
Post a Comment